Ocular diseases seriously affect patients' vision and life quality, with a global morbidity of
over 43 million blindness. However, efficient drug delivery to treat ocular diseases …

Nanomaterials and targeted drug delivery vehicles improve the therapeutic index of drugs
and permit greater control over their pharmacokinetics, biodistribution, and bioavailability …

Engineering smart nano-therapeutics for re-epithelialisation of chronic wounds facilitates the
wound healing process. However, due to excessive oxidative stress damage and persistent …

Presently, different types of eye diseases, such as glaucoma, myopia, infection, and dry eyes
are treated with topical eye drops. However, due to ocular surface barriers, eye drops …

The eye has anatomical structures that function as robust static and dynamic barriers,
limiting the penetration, residence time, and bioavailability of medications administered …

Proteases are important biomarkers and targets for the diagnosis and treatment of disease.
The advantageous properties of semiconductor quantum dots (QDs) have made these …

Biomacromolecules have long been at the leading edge of academic and pharmaceutical
drug development and clinical translation. With the clinical advances of new therapeutics …

Endothelial cells (ECs) are pivotal in maintaining vascular health, regulating hemodynamics,
and modulating inflammatory responses. Nanocarriers hold transformative potential for …

The complexity of the human eye structure poses challenges in the diagnosis and treatment
of ocular diseases, especially the low efficiency of ocular drug delivery. With the continuous …

Ocular delivery is the most challenging aspect in the field of pharmaceutical research. The
major hurdle for the controlled delivery of drugs to the eye includes the physiological static …